NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Eligible age
0.5–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T lymphocytes (CTLs) and immune-modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negative in B-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.
Sponsor: Shenzhen Geno-Immune Medical Institute
You may qualify if…
- ✓ 1. Age older than 6 months.
- ✓ 2. High-burden (≥30% blast cells) B-ALL tumor specimen for clonal IgH identification and CTL/DC vac preparation is required
- ✓ 3. Expression of CD19, CD22, CD20, CD10 or CD123 is determined in malignant cells by flow cytometry or immuno-histochemical staining.
- ✓ 4. Karnofsky performance status (KPS) score is higher than 60 and life expectancy \> 3 months.
- ✓ 5. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5x upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x upper limit of normal, total bilirubin ≤ 2.0mg/dL.
- ✓ 6. No cell separation contraindications.
- ✓ 7. Abilities to understand and the willingness to provide written informed consent.
You may not qualify if…
- ✕ 1. Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection.
- ✕ 2. Active bacterial, fungal or viral infection not controlled by adequate treatment.
- ✕ 3. Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- ✕ 4. Pregnant or nursing women may not participate.
- ✕ 5. History of glucocorticoid for systemic therapy within the week prior to entering the test.
- ✕ 6. Previously treatment with any gene therapy products.
- ✕ 7. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.
Source: ClinicalTrials.gov · NCT05262673 · last updated 2026-06-23